Ghaziabad Online

Extensive-Stage Small Cell Lung Cancer Pipeline and Clinical Trial Phases | 40+ Companies and 40+ Drugs

 Breaking News
  • No posts were found

Extensive-Stage Small Cell Lung Cancer Pipeline and Clinical Trial Phases | 40+ Companies and 40+ Drugs

January 12
22:01 2023
Extensive-Stage Small Cell Lung Cancer Pipeline and Clinical Trial Phases | 40+ Companies and 40+ Drugs

DelveInsight’s, “Extensive Stage Small Cell Lung Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Extensive Stage Small Cell Lung Cancer pipeline landscape. It covers the Extensive Stage Small Cell Lung Cancer pipeline drug profiles, including Extensive Stage Small Cell Lung Cancer clinical trial and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Extensive Stage Small Cell Lung Cancer Pipeline Report

  • DelveInsight’s Extensive Stage Small Cell Lung Cancer Pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Extensive Stage Small Cell Lung Cancer treatment.
  • The leading Extensive Stage Small Cell Lung Cancer companies such as Genentech, Bristol-Myers Squibb, Henilus Biotech, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., BioNTech SE, Xencor, Inc., Haihe Biopharma Co., Ltd., Taizhou HoudeAoke Biomedical Co., Ltd., Celgene, Xcovery Holding Company, LLC, Lee’s Pharmaceutical Limited, Merck & Co, Astex Pharmaceuticals, Daiichi Sankyo, BeiGene, Jiangsu HengRui Medicine, Merck Sharp & Dohme, Qilu Pharmaceutical, AstraZeneca, Innovent Biologics, Kartos Therapeutics, Imago BioSciences, Aeglea Biotherapeutics, Akeso Biopharma, Rhizen Pharmaceuticals, Novartis, Amgen, Shanghai Junshi Bioscience, Eli Lilly and company, Impact Therapeutics, Luye Pharma, Pfizer, Genprex and others are evaluating novel small cell lung cancer treatment drugs candidate to improve the treatment landscape.
  • The promising Extensive Stage Small Cell Lung Cancer pipeline therapies in various stages of development include LY 2510924, Tiragolumab, BMS-986012, Serplulimab, SYHA1807, BNT411, XmAb18087, Vorolanib, AL3810, LP002, CC-90011, Tremelimumab, ZKAB001, Pembrolizumab, Guadecitabine, KRT-232, Pegzilarginase, Bomedemstat, Tarlatamab, Toripalimab, LY3295668, IMP4297, LY01610, Talazoparib, AK112, RP12146, Sintilimab, and others.
  • The Extensive Stage Small Cell Lung Cancer Companies and academics are working to assess challenges and seek opportunities that could influence Extensive Stage Small Cell Lung Cancer (ESCLC) R&D. The Extensive Stage Small Cell Lung Cancer pipeline therapies under development are focused on novel approaches to treat/improve Extensive Stage Small Cell Lung Cancer.

 

Explore more about the latest breakthroughs in the Extensive Stage Small Cell Lung Cancer Treatment Landscape @ Extensive Stage Small Cell Lung Cancer Pipeline Outlook Report

 

Extensive-Stage Small Cell Lung Cancer Overview

Extensive Stage Small Cell Lung Cancer is in the stage where it has spread to other parts of the body, such as the other lung or the brain. Without treatment, the average life expectancy for a person with an extensive-stage small cell lung cancer diagnosis is two to four months. The liver, adrenal glands, and bone are also common sites of metastasis. Though extensive-stage small cell lung cancer cannot be cured and has a poor prognosis, it may respond to chemotherapy and newer treatments. Because the cancer has spread, the main treatment for extensive stage SCLC is chemotherapy. Common chemo drugs used for ESCLC are: carboplatin and cisplatin. Other therapies used to treat ESCLS include: immunotherapy and radiation therapy.

 

Latest Breakthroughs in the Extensive-Stage Small Cell Lung Cancer Treatment Landscape

  • In April 2022, Shanghai Henlius Biotech, announced that the New Drug Application of HANSIZHUANG (serplulimab), a novel anti-PD-1 monoclonal antibody (mAb) independently developed by the company, in combination with chemotherapy for the first-line treatment of Extensive-stage Small Cell Lung cancer (ES-SCLC) has been accepted by the National Medical Products Administration (NMPA). Henlius has also planned to file MAA in the EU in 2022. In April 2022, FDA has granted Orphan-Drug Designation for HANSIZHUANG for the treatment of SCLC, benefiting the continuous development of HANSIZHUANG.
  • In March 2022, Akesobio entered into a collaboration agreement with Shenzhen Chipscreen Biosciences to conduct a Phase Ib/II clinical study of combination therapy of Cadonilimab (PD-1/CTLA-4 bispecific antibody, AK104) and Chiauranib (a highly selective Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor) in patients with ES-SCLC which progressed on combination therapy of platinum-based chemotherapy and PD-(L) 1 inhibitor as first-line treatment.
  • In October 2021, Jiangsu Hengrui Pharmaceuticals reported positive data of a Phase III study, demonstrating that the investigational anti-PD-L1 mAb adebrelimab (SHR-1316) in combination with etoposide and carboplatin (EC) compared with placebo in combination with EC met the primary endpoint of overall survival (OS) as first-line treatment for extensive-stage small cell lung cancer. Hengrui has submitted a pre-New Drug Application meeting request to China National Medical Products Administration based on the positive data.
  • BioNTech is evaluating BNT411 as a monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-naïve extensive-stage small cell lung cancer. In July 2021, BNT411 demonstrated an acceptable safety profile at all doses tested as a monotherapy and in combination with atezolizumab, carboplatin and etoposide.
  • In March 2021, China’s National Medical Products Administration cleared Lee’s Pharm to conduct a Phase III, multicenter, randomized, double blinded, parallel-group clinical trial of Socazolimab (anti-PD-L1 monoclonal antibody, formerly known as ZKAB001) combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.

 

Extensive Stage Small Cell Lung Cancer Emerging Drugs

• LY 2510924: Eli Lilly and Company

• Tiragolumab: Genentech

 

Discover the recent advances in Extensive Stage Small Cell Lung Cancer Treatment Drugs @ Extensive Stage Small Cell Lung Cancer Ongoing Clinical Trial Analysis

 

Extensive Stage Small Cell Lung Cancer Pipeline Therapeutics Analysis

There are approx. 40+ key companies which are developing the therapies for Extensive Stage Small Cell Lung Cancer (ESCLC). The companies which have their Extensive Stage Small Cell Lung Cancer (ESCLC) drug candidates in the most advanced stage, i.e. phase III include, Genentech.

 

DelveInsight’s Extensive Stage Small Cell Lung Cancer Pipeline Report covers around 40+ products under different phases of clinical development like-

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

 

Learn more about the novel and Extensive Stage Small Cell Lung Cancer Emerging Therapies @ Extensive Stage Small Cell Lung Cancer Treatment Landscape

 

Scope of the Extensive Stage Small Cell Lung Cancer Pipeline Report

  • Coverage- Global
  • Extensive Stage Small Cell Lung Cancer Companies- Genentech, Bristol-Myers Squibb, Henilus Biotech, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., BioNTech SE, Xencor, Inc., Haihe Biopharma Co., Ltd., Taizhou HoudeAoke Biomedical Co., Ltd., Celgene, Xcovery Holding Company, LLC, Lee’s Pharmaceutical Limited, Merck & Co, Astex Pharmaceuticals, Daiichi Sankyo, BeiGene, Jiangsu HengRui Medicine, Merck Sharp & Dohme, Qilu Pharmaceutical, AstraZeneca, Innovent Biologics, Kartos Therapeutics, Imago BioSciences, Aeglea Biotherapeutics, Akeso Biopharma, Rhizen Pharmaceuticals, Novartis, Amgen, Shanghai Junshi Bioscience, Eli Lilly and company, Impact Therapeutics, Luye Pharma, Pfizer, Genprex, and others.
  • Extensive Stage Small Cell Lung Cancer Therapies- LY 2510924, Tiragolumab, BMS-986012, Serplulimab, SYHA1807, BNT411, XmAb18087, Vorolanib, AL3810, LP002, CC-90011, Tremelimumab, ZKAB001, Pembrolizumab, Guadecitabine, KRT-232, Pegzilarginase, Bomedemstat, Tarlatamab, Toripalimab, LY3295668, IMP4297, LY01610, Talazoparib, AK112, RP12146, Sintilimab, and others
  • Extensive Stage Small Cell Lung Cancer Segmentation: Phases, Molecule Type, Route of Administration, Mechanism of Action, Product Type

 

Table of Content

1. Introduction

2. Executive Summary

3. Extensive Stage Small Cell Lung Cancer Overview

4. Extensive Stage Small Cell Lung Cancer Pipeline Therapeutics

5. Extensive Stage Small Cell Lung Cancer Therapeutic Assessment

6. Late Stage Products (Phase III)

7. Tiragolumab: Genentech

8. Mid Stage Products (Phase II)

9. LY 2510924: Eli Lilly and Company

10. Early Stage Products (Phase I)

11. SYHA 1807: CSPC ZhongQi Pharmaceutical Technology

12. Inactive Products

13. Extensive Stage Small Cell Lung Cancer Key Companies

14. Extensive Stage Small Cell Lung Cancer Key Products

15. Extensive Stage Small Cell Lung Cancer Unmet Needs

16. Extensive Stage Small Cell Lung Cancer Market Drivers and Barriers

17. Extensive Stage Small Cell Lung Cancer Future Perspectives and Conclusion

18. Extensive Stage Small Cell Lung Cancer Analyst Views

19. Extensive Stage Small Cell Lung Cancer Key Companies

20. Appendix

 

Dive deep into rich insights for new drugs for Extensive Stage Small Cell Lung Cancer Treatment, visit Extensive Stage Small Cell Lung Cancer Key Companies and Therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/